Corient Private Wealth LP Reduces Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Corient Private Wealth cut its Regeneron stake by 23.9% in the second quarter, selling 4,315 shares and retaining 13,758 shares valued at approximately $8.6 million.
• Regeneron reported stronger-than-expected quarterly results, with earnings of $14.29 per share and revenue of $4.29 billion. Analysts maintain a “Moderate Buy” consensus and an average price target of $800.36.
• The FDA approved Regeneron’s Pasatru for an ultra-rare genetic disorder, expanding its commercial pipeline, while failed melanoma trials have created litigation and replacement-growth concerns.

Corient Private Wealth LP cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 23.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 13,758 shares of the biopharmaceutical company's stock after selling 4,315 shares during the quarter. Corient Private Wealth LP's holdings in Regeneron Pharmaceuticals were worth $8,579,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. BlackRock Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at about $5,682,636,000. Dodge & Cox raised its position in shares of Regeneron Pharmaceuticals by 1.0% during the fourth quarter. Dodge & Cox now owns 4,596,358 shares of the biopharmaceutical company's stock valued at $3,547,791,000 after buying an additional 45,513 shares during the last quarter. Franklin Resources Inc. grew its stake in Regeneron Pharmaceuticals by 4.4% during the fourth quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company's stock valued at $1,975,990,000 after acquiring an additional 106,861 shares in the last quarter. Nuveen LLC increased its holdings in shares of Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company's stock worth $1,551,858,000 after purchasing an additional 835,240 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in Regeneron Pharmaceuticals by 142.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company's stock worth $1,504,991,000 after acquiring an additional 1,144,887 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on REGN shares. Sanford C. Bernstein raised Regeneron Pharmaceuticals to a "hold" rating in a research note on Wednesday, July 29th. Royal Bank Of Canada boosted their price objective on Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a "sector perform" rating in a report on Friday, July 31st. Truist Financial upped their price objective on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a "buy" rating in a research report on Friday, July 31st. HSBC reduced their target price on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a "buy" rating on the stock in a research note on Monday, July 6th. Finally, Weiss Ratings reiterated a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. Fifteen research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $800.36.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder that causes abnormal bone growth. In a 56-week Phase 3 trial, the approved dose reduced disease-related bone formation, giving Regeneron a new commercial opportunity and strengthening its rare-disease pipeline. However, the small patient population likely limits the drug’s near-term earnings contribution. Can Regeneron’s Rare-Disease Win Move the Earnings Needle?
• Neutral Sentiment: An investor letter highlighted Regeneron’s response to mixed results from its melanoma drug trials, including adjustments to its development strategy. The update offers limited new information but underscores the importance of replacing potential value lost from the failed program. Regeneron Adjusts Course Amid Mixed Results in Melanoma Drug Trials
• Negative Sentiment: Several law firms announced or promoted a securities-fraud class action related to disclosures surrounding Regeneron’s failed Phase 3 melanoma trial. The failure reportedly erased approximately $11 billion in market capitalization and prompted allegations that investors were misled about the program. The repeated notices, all citing a September 14, 2026 lead-plaintiff deadline, add reputational and potential litigation-cost risks, although they do not represent a finding of wrongdoing. Regeneron Securities Fraud Class Action Filed Faruqi Shareholder Notice

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of the business's stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the transaction, the director owned 17,303 shares of the company's stock, valued at $11,249,545.45. The trade was a 1.14% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $320,000.00. Following the completion of the transaction, the director owned 603 shares of the company's stock, valued at approximately $482,400. This represents a 39.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,400 shares of company stock valued at $1,090,030 in the last ninety days. Company insiders own 6.97% of the company's stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $794.19 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The company has a 50-day moving average of $717.52 and a 200 day moving average of $717.95. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $847.00. The firm has a market cap of $81.77 billion, a PE ratio of 19.63, a price-to-earnings-growth ratio of 1.35 and a beta of 0.22.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts' consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm's revenue for the quarter was up 16.7% compared to the same quarter last year. During the same quarter last year, the company earned $12.81 earnings per share. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be issued a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals's payout ratio is 9.29%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source